GlaxoSmithKline to acquire Reliant
From Times Wire Reports
GlaxoSmithKline will buy heart drug specialist Reliant Pharmaceuticals Inc. for $1.65 billion in cash, the company said. GSK expects the transaction will add to earnings in 2008 and create additional value in following years.
Privately held Reliant develops specialty medicines combating heart disease and holds U.S. rights to Lovaza, a treatment for adult patients with very high levels of triglycerides.
